Résumé
Abnormalities in connectivity are thought to contribute to the symptoms of schizophrenia. Accumulating evidence suggests that antipsychotic medication affects both subcortical and cortical grey and white matter volumes. The goal of this study was to investigate the effects of antipsychotic medication on two white matter tracts: a subcortical-cortical tract, the anterior and posterior limbs of the internal capsule; and a cortical-cortical tract, the corpus callosum. Magnetic resonance imaging was conducted on 10 chronic schizophrenia patients treated with typical antipsychotics and 20 healthy controls at baseline. Patients were switched to olanzapine and both groups were rescanned after 1 year. At baseline, the volume of the anterior limb of the internal capsule was 24% smaller in typical-treated patients than controls (p = 0.009). Patients treated with greater amounts of chlorpromazine-equivalent daily dosage had smaller anterior internal capsule volumes at baseline (r = -0.65, p = 0.04). At follow-up, after being switched to olanzapine, there were no significant differences between patients and controls. Patients with schizophrenia had a significant 25% increase in anterior internal capsule volume from baseline to follow-up compared with controls (p = 0.04). These effects were most prominent in the anterior limb of the internal capsule, which consists of fronto-thalamic pathways, and were not statistically significant in the posterior limb of the internal capsule or corpus callosum. Olanzapine may be effective in normalizing fronto-thalamic structural connectivity in schizophrenia.
Langue d'origine | English |
---|---|
Pages (de-à) | 621-629 |
Nombre de pages | 9 |
Journal | Journal of Psychopharmacology |
Volume | 25 |
Numéro de publication | 5 |
DOI | |
Statut de publication | Published - mai 2011 |
Note bibliographique
Funding Information:Dr Honer reports receiving consulting fees or sitting on paid advisory boards for In-silico, Wyeth, Janssen, Novartis and AstraZeneca, receiving lecture fees from Janssen and AstraZeneca, and educational grant support from Janssen, Eli Lilly and AstraZeneca. Dr Barr has acted as a consultant to Eli Lilly Canada. Dr. Kopala reports sitting on paid advisory boards for AstraZeneca and Pfizer and receiving lecture fees from Janssen, AstraZeneca, and Pfizer. Drs Kopala and Smith have acted as consultants for Syreon Corporation. No other authors report any potential conflicts of interest.
Funding Information:
Partial funding for MRI scanning was provided by investigator-initiated grants from Janssen-Ortho Canada and Eli Lilly Canada. The Queen Elizabeth II Hospital Science Research Foundation and Department of Psychiatry, Dalhousie University, provided additional funds for scanning. Dr Honer was supported by grant NET-54013 from the Canadian Institutes of Health Research, the National Alliance for Research on Schizophrenia and Depression, the Stanley Medical Research Institute and the MIND Foundation of British Columbia. Dr Kopala was supported by a Clinician Scientist Award from Dalhousie University.
ASJC Scopus Subject Areas
- Pharmacology
- Psychiatry and Mental health
- Pharmacology (medical)